Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>In 1H FY03/25, revenue increased 5.4% YoY to JPY30.8bn, while operating profit declined 3.9% YoY to JPY1.3bn.</li><li>Segment profit for scaffolding equipment rentals grew 0.4% YoY to JPY1.3bn, with revenue up 15.1% YoY to JPY12.5bn.</li><li>Electronic Equipment segment revenue fell 10.0% YoY to JPY2.4bn, resulting in a segment loss of JPY326mn.</li></ul>

In 1H FY03/25, revenue increased 5.4% YoY to JPY30.8bn, while operating profit declined 3.9% YoY to JPY1.3bn.Segment profit for scaffolding equipment rentals grew 0.4% YoY to JPY1.3bn, with revenue up 15.1% YoY to JPY12.5bn.Electronic Equipment segment revenue fell 10.0% YoY to JPY2.4bn, resulting in a segment loss of JPY326mn.

Alinco Inc (5933 JP): 1H FY03/25 flash update

'Quantamental' Japan Specialist, LightStream Research

Campbell Gunn

'Quantamental' Japan Specialist

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Thematic (Sector/Industry)

<div>
<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/147/085/original/2020-07-21_06-31-46.png?1595280841" class="editor-image img-responsive" data-smartkarma-image-id="147085"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/147/086/original/2020-07-21_06-31-04.png?1595281006" class="editor-image img-responsive" data-smartkarma-image-id="147086"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/147/087/original/2020-07-21_06-44-10.png?1595281527" class="editor-image img-responsive" data-smartkarma-image-id="147087"></figure><div class="content-caption">Source • Japan Analytics</div>
<p><strong>Genky DrugStores (9267 JP)</strong> - Genky, listed in December 2017 and the eleventh largest listed drugstore chain in Japan, <span>was nearly Oversold in the first quarter.</span><span> As a result, the shares have been the best performing in the fifteen-string Peer Group over the last three months. The company's upward revisions to sales and operating profits of 9% and 21%, respectively match peer-trends. The recent share price rally has brought Genky back into line. The company is, however, one of only three chains that fail to earn a positive residual return on Net Operating Assets, Genky also has the highest debt/equity ratio of any listed chain. The company does not deserve any peer-premium, and we would sell into any revision-induced strength.</span></p>
<p style="text-align: center;"><strong>DAILY STATS</strong></p>
</div><hr><div><p style="text-align: center;"><strong>2 Quarterly Results</strong></p></div><div><ul>
<li>
<strong>Results Score</strong>: 0 Positive / 0 Neutral / 2 Negative</li>
<li>
<strong>Average Results Score Change:</strong> -7.0</li>
<li>
<strong>Average % Change in Revenue:</strong> -12..% Quarter YoY / +0.8% Rolling TTM YoY</li>
<li>
<strong>Average Operating Profit Margin Change:</strong> +0.1ppt</li>
<li>
<strong>Percentage Making Quarterly Losses:</strong> 0%</li>
</ul></div><hr><div><p style="text-align: center;"><br><strong>4 Annual • 8 Interim Forecasts/Revisions</strong></p></div><div><ul>
<li>
<strong>Annual Forecast/Revision Score:</strong> 1 Positive / 1 Neutral / 2 Negative</li>
<li>
<strong>Interim Forecast/Revision Score Change:</strong> 2 Positive / 0 Neutral / 6 Negative</li>
<li>
<strong>Average Forecast/Revision Score Change:</strong> -6.8</li>
</ul></div>


Source • Japan Analytics
Genky DrugStores (9267 JP) - Genky, listed in December 2017 and the eleventh largest listed drugstore chain in Japan, was nearly Oversold in the first quarter. As a result, the shares have been the best performing in the fifteen-string Peer Group over the last three months. The company's upward revisions to sales and operating profits of 9% and 21%, respectively match peer-trends. The recent share price rally has brought Genky back into line. The company is, however, one of only three chains that fail to earn a positive residual return on Net Operating Assets, Genky also has the highest debt/equity ratio of any listed chain. The company does not deserve any peer-premium, and we would sell into any revision-induced strength.
DAILY STATS
2 Quarterly Results

Results Score: 0 Positive / 0 Neutral / 2 Negative

Average Results Score Change: -7.0

Average % Change in Revenue: -12..% Quarter YoY / +0.8% Rolling TTM YoY

Average Operating Profit Margin Change: +0.1ppt

Percentage Making Quarterly Losses: 0%
 4 Annual • 8 Interim Forecasts/Revisions

Annual Forecast/Revision Score: 1 Positive / 1 Neutral / 2 Negative

Interim Forecast/Revision Score Change: 2 Positive / 0 Neutral / 6 Negative

Average Forecast/Revision Score Change: -6.8


🇯🇵 JAPAN • Results & Revisions 20th July - Genki Genky, Alinco, Komatsu Wall, GMO-AD Partners

Japan

ALINCO INCORPORATED manufactures and leases steel and metal products.  The Company's main products are scaffolds and other metal products mainly used at construction sites.  Alinco also produces steps, stepladders, and electronic equipment.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alinco Inc (5933 JP)